RWF_D6060C00001

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects with Selected Advanced Solid Tumors

This is a first-time-in-human (FTiH) Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study of MEDI0562 to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity in adult subjects with selected advanced solid tumors.

Inclusion Criteria:

* Subjects must have confirmed recurrent or metastatic solid tumor that is deemed to be incurable by local therapy. Subjects with recurrent disease who have had disease progression after curative treatment for locoregionally advanced disease are eligible. Subjects must have progressive disease and may have received up to 4 prior systemic treatment regimens including both standard of care and investigational therapies. Subjects with recurrent disease may have received prior systemic therapy as part of induction, chemoradiotherapy, or adjuvant chemotherapy for potential curative treatment.

* Subjects must have at least 1 measurable lesion.

Phase I
NCT02318394
Oncology
Multiple Tumor Types
Rom Leidner, M.D.
MedImmune, LLC
Katie Tripp
  • Oncology and Hematology Care Eastside